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harmacological
ifferences of Glitazones
oes Peroxisome Proliferator-
ctivated Receptor- Activation
ake the Difference?*
lrich Kintscher, MD
erlin, Germany
litazones or thiazolidinediones (TZDs) are insulin-
ensitizing drugs widely used in oral antidiabetic therapy
1). Currently, 2 substances, pioglitazone and rosiglitazone,
re available in daily clinical practice. Both glitazones act as
igands for the nuclear hormone receptor peroxisome
roliferator-activated receptor (PPAR) and regulate its
ranscriptional activity. On the basis of recently published
eta-analyses and trials investigating surrogate parameters
or cardiovascular risk, the question has been raised whether
ioglitazone and rosiglitazone exert different clinical and
harmacological actions. A controversially discussed meta-
nalysis reported an increased rate of myocardial infarction
ith rosiglitazone, although this rate was not observed in
imilar analysis with pioglitazone (2–4).
See page 869
In addition, a previously published head-to-head com-
arison of both TZDs in the GLAI (Comparison of Lipid
nd Glycemic Effects of Pioglitazone and Rosiglitazone in
atients With Type 2 Diabetes and Dyslipidemia) study
howed that pioglitazone has favorable effects on diabetic
yslipidemia, including a lowering of triglycerides and an
ncreasing of high-density lipoprotein cholesterol when
ompared with rosiglitazone (5). On the basis of these data,
t has been speculated that one of the underlying pharma-
ological mechanisms for these differences might be the
ranscriptional activation of the other PPAR isoform,
PAR, by glitazones in addition to PPAR activation.
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ngelheim, Berlin Chemie, and Merck, Sharp & Dohme.In this issue of the Journal, an elegant pre-clinical and
linical study is presented by Orasanu et al. (6) character-
zing PPAR activation by pioglitazone in the context of
nti-inflammatory actions. A comparison between pioglita-
one and rosiglitazone has been included in the pre-clinical
art of this study. The authors convincingly demonstrate
hat pioglitazone inhibits tumor necrosis factor-alpha–
nduced vascular cell adhesion molecule (VCAM)-1 tran-
cription, which is one of the major adhesion molecules
nvolved in atherogenesis, whereas rosiglitazone has no
ffect. By using microvascular endothelial cells from
PAR-deficient mice, the authors prove that PPAR is
equired for pioglitazone’s action on VCAM-1.
In consonance, pioglitazone activates the PPAR ligand
inding domain (LBD) in a concentration-dependent man-
er, but rosiglitazone lacks this activation. Following a
ranslational approach, Orasanu et al. (6) corroborate the
PAR-dependent suppression of VCAM-1 by pioglita-
one in PPAR-deficient and wild-type mice treated with
ioglitazone. Finally, they demonstrate a potential clinical
elevance of their results in a clinical study in 34 diabetic
atients treated either with pioglitazone or placebo for 16
eeks. Pioglitazone treatment prevented an increase in
lasma soluble VCAM-1 levels. In summary, this study
hows for the first time that pioglitazone-induced PPAR
ctivation is involved in anti-inflammatory actions of this
ZD.
The study by Orasanu et al. (6) doubtlessly shows that
ioglitazone activates PPAR in vitro and that this activa-
ion is relevant for VCAM-1 regulation in vitro and in mice.
n addition, the authors demonstrate that PPAR activa-
ion in vitro is absent with rosiglitazone. These data
ubstantially contribute to our understanding about the
harmacology of TZDs. In vitro PPAR activation by
litazones has been previously shown by Sakamoto et al. (7).
owever, in the past, glitazone-mediated PPAR activa-
ion has been mainly connected to the actions of these
ompounds on diabetic dyslipidemia. Anti-inflammatory
ctions as the result of PPAR activation are novel and
mportant mechanisms of action of pioglitazone.
The study is missing a direct comparison of the 2 TZDs
n the mouse model and, more importantly, in the clinical
tudies (6). In their clinical study, the authors show that a
lasma soluble VCAM-1 increase in the placebo group is
lmost completely prevented by pioglitazone treatment.
ecause rosiglitazone is missing in the clinical study, one
as to be cautious with the interpretation of these data with
espect to clinical differences among the TZDs. Anti-
nflammatory actions of TZDs have been described for both
ompounds, including a decrease in high-sensitivity
-reactive protein, which leads to the question, how clini-
ally relevant is the PPAR-mediated VCAM-1 regulation
y pioglitazone? The answer is beyond the scope of the work
f Orasanu et al. (6). Although this novel mechanism
efinitely contributes an additional and important part to
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f a head-to-head comparison between pioglitazone and
osiglitazone in the mouse experiments and the clinical
tudies does not allow any major implications from these
ata for the understanding of pharmacological differences
nd the distinction of cardiovascular actions between the 2
ZDs.
From a molecular point of view, the question remains:
oes PPAR activation really make a difference among
he glitazones? The molecular mechanisms underlying
Figure 1 Pharmacological Targets of Glitazones: Selective PPAR
Pioglitazone and rosiglitazone bind to the peroxisome proliferator-activated rece
ligand-specific and common gene expression and pharmacological responses (
zone-mediated PPAR activation regulates the indicated endothelial genes. IB
molecule 1. Figure illustration by Rob Flewell.litazone-mediated PPAR activation are complex and only sartially understood. Like other nuclear hormone receptors,
PAR is in a basal state bound to so-called corepressor
roteins such as nuclear receptor corepressor (8). After
inding within the LBD, PPAR ligands such as TZDs
nduce its heterodimerization with retinoid x-receptor  and
ts subsequent interaction with co-activators such as steroid
eceptor coactivators, followed by binding to PPAR re-
ponse elements within target gene promoters (9).
Summarized in this concept of selective PPAR modu-
ation, ligand-specific cofactor binding determines ligand-
dulation and PPAR Activation
PPAR)-, and recruit a ligand-specific set of nuclear cofactors resulting in
addition, both glitazones have been shown to activate PPAR (6). Pioglita-
hibitor of B; RXR  retinoid X receptor; VCAM-1  vascular cell adhesion Mo
ptor (
9). In
  inpecific gene transcription patterns, which lead to ligand-
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Editorial Comment September 2, 2008:882–4pecific biological responses (Fig. 1). More importantly,
inor differences in the chemical structure of PPAR
igands such as in the structures of different glitazones
esult in marked differences of ligand-bound LBD con-
ormation, which then influences cofactor binding and
ene expression. Along this line, major differences in
ene expression pattern between rosiglitazone and pio-
litazone have been detected in adipocytes and may
xplain distinct biological and clinical actions (10).
Data about PPAR-cofactor binding and ligand-specific
ene expression patterns in monocyte/macrophages, endo-
helial cells, and vascular smooth muscle cells are limited.
owever, one might hypothesize that ligand-specific re-
ponses based on selective PPAR modulation not only
ccur in one given tissue such as adipose tissue but might
lso be present in all tissues, including cardiovascular or-
ans. The interactions between glitazones and the PPAR-
BD allows a wide range of ligand specificity, which
ubsequently results in ligand-specific responses without
aking into account a potential binding to another PPAR
soform.
In summary, the transcriptional activation of PPAR by
litazones comprises only one pharmacological characteris-
ic of ligand specificity. However, keeping the concept of
elective PPAR modulation in mind, glitazone-PPAR-
BD interactions may provide an additional molecular level
f ligand-specific responses. Therefore, future studies are
bsolutely required to focus not only on the interaction with
ther PPAR isoforms but also, more importantly, on
litazone-PPAR-LBD-cofactor interaction in different
ealthy and diseased states. Such data will be tremendously
elpful to understand current differences between glitazonesnd to develop new ligands for the PPAR with improved
linical efficacy and less side effects.
eprint requests and correspondence: Dr. Ulrich Kintscher,
enter for Cardiovascular Research, Institute of Pharmacology,
harité–Universitätsmedizin Berlin, Hessische Str. 3-4, 10115
erlin, Germany. E-mail: ulrich.kintscher@charite.de.
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